Blue Capital’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$468K Sell
1,788
-2
-0.1% -$513 0.29% 90
2026
Q2
$450K Sell
1,790
-571
-24% -$123K 0.29% 76
2026
Q1
$513K Buy
2,361
+573
+32% +$127K 0.34% 70
2025
Q4
$409K Buy
1,788
+14
+0.8% +$3.19K 0.29% 66
2025
Q3
$411K Buy
1,774
+104
+6% +$21.2K 0.31% 67
2025
Q2
$310K Buy
+1,670
New +$310K 0.22% 69
2024
Q4
$297K Buy
+1,670
New +$307K 0.21% 90

Other funds holding ABBV

Blue Capital's ABBV Position: Q3 2026 in Review

Blue Capital reduced its AbbVie (ABBV) stake by 0.11% in Q3 2026, selling an estimated $513 and leaving 1,788 shares worth $468K. The position accounts for 0.29% of the portfolio, ranked #90.

Blue Capital first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. The position peaked at $513K in Q1 2026. 3,830 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Blue Capital held 1,788 shares of AbbVie worth $468K as of Q3 2026.
  • Blue Capital sold 2 AbbVie shares in Q3 2026, an estimated $513.
  • AbbVie made up 0.29% of Blue Capital's portfolio in Q3 2026, its #90 holding.
  • Blue Capital first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • Blue Capital's AbbVie position peaked at $513K in Q1 2026.
  • 3,830 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Blue Capital's 13F filing for Q3 2026, filed 13 Oct 2026.